InsiderSignalSign in
← Insider buys

XFOR

X4 Pharmaceuticals, Inc. · Healthcare

Insiders bought $250K of X4 Pharmaceuticals, Inc. in the last 12 months

1 insider bought on 1 day.

$250KBought, 12 mo
$463KSold, 12 mo
$321.2MMarket cap
Follow XFOR

XFOR over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

XFOR after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Every filing

38 insider filings since 2020, newest first

XFORSell

David Kirske · Chief Financial Officer

$34K−7.0%Oct 5
XFORSell

John Volpone · President

$109K−8.5%Aug 13
XFORSell

Adam R Craig · Executive Chair

$211K−12.6%Aug 13
XFORSell

David Kirske · Chief Financial Officer

$36K−4.8%Jul 1
XFORSell

David Kirske · CFO

$73K−9.0%May 13
XFORBuy

Adam R Craig · Executive Chair

$250K+30.0%Oct 27
XFORSell

Adam S. Mostafa · CFO

$127K−100.0%Oct 8
XFORSell

Paula Ragan · President and CEO

$132K−18.0%Oct 8
XFORSell

Mary Dibiase · COO

$38K−13.0%Oct 8
XFORSell

Arthur Taveras · Chief Scientific Officer

$43K−17.0%Oct 8
XFORSell

Paula Ragan · President and CEO

$44K−6.0%Mar 11
XFORSell

Adam S. Mostafa · CFO

$46K−100.0%Mar 11
XFORSell

Adam S. Mostafa · CFO

$28K−35.0%Feb 12
XFORSell

Paula Ragan · President and CEO

$182K−22.0%Nov 3
XFORSell

Adam S. Mostafa · CFO

$168K−74.0%Nov 3
XFORSell

Mary Dibiase · COO

$49K−18.0%Nov 3
XFORSell

Arthur Taveras · Chief Scientific Officer

$49K−21.0%Nov 3
XFORBuy

Michael S Wyzga · Director

$30K+48.0%Aug 22
XFORSell

Murray Stewart · Interim Chief Medical Officer

$138K−47.0%Aug 11
XFORSell

Adam S. Mostafa · CFO

$44K−36.0%Mar 13
XFORSell

Paula Ragan · President and CEO

$42K−8.0%Mar 13
XFORSell

Adam S. Mostafa · CFO

$26K−16.0%Feb 15
XFORSell

Adam S. Mostafa · CFO

$55K−8.0%Aug 19
XFORSell

Derek M Meisner · General Counsel

$42K−10.0%Aug 19
XFORSell

Paula Ragan · President and CEO

$69K−3.0%Aug 19
XFORSell

Paula Ragan · President and CEO

$78K−3.0%Jul 16
XFORSell

Adam S. Mostafa · CFO

$38K−4.0%Jun 25
XFORSell

Derek M Meisner · General Counsel

$29K−5.0%Jun 25
XFORSell

Derek M Meisner · General Counsel

$33K−5.0%Jun 17
XFORSell

Adam S. Mostafa · CFO

$42K−4.0%Jun 17
XFORSell

Paula Ragan · President and CEO

$39K−1.0%Jun 2
XFORSell

Paula Ragan · President and CEO

$34K−2.0%Dec 28
XFORSell

Adam S. Mostafa · CFO

$77K−27.0%Sep 22
XFORSell

Renato Skerlj · Chief Scientific Officer

$47K−12.0%Sep 10
XFORSell

Paula Ragan · President and CEO

$71K−3.0%Sep 10
XFORSell

Derek M Meisner · General Counsel

$67K−33.0%Sep 10
XFORSell

Paula Ragan · President and CEO

$144K−7.0%Jun 3
XFORSell

Paula Ragan · President and CEO

$26K−1.0%Mar 3
About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.